Mitigating the Opioid Epidemic: The Role of Cannabinoids in Chronic Pain Management—A Systematic Review and Meta-Analysis of Clinical Evidence and Mechanisms

Mitigating the Opioid Epidemic: The Role of Cannabinoids in Chronic Pain Management—A Systematic Review and Meta-Analysis of Clinical Evidence and Mechanisms | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Systematic Review Mitigating the Opioid Epidemic: The Role of Cannabinoids in Chronic Pain Management—A Systematic Review and Meta-Analysis of Clinical Evidence and Mechanisms Julian Yin Vieira Borges This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4736592/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background As the medical community seeks alternative pain management strategies, cannabinoids have emerged as a potential option. This review discusses the role of cannabinoids in chronic pain management and their potential to be an alternative treatment in pain medicine. Objectives To evaluate the efficacy and safety of cannabinoids in chronic pain management, explore their potential to reduce opioid use, and identify the mechanisms by which cannabinoids exert their analgesic effects. Additionally, the review seeks to highlight the clinical implications and limitations of using cannabinoids as an alternative to opioids. Methods A comprehensive review of existing literature was conducted, focusing on various types of studies. Data were extracted and analyzed to assess the efficacy, safety, and potential opioid-sparing effects of cannabinoids. Mechanistic insights were also explored to understand how cannabinoids modulate pain. Results Cannabinoids have shown efficacy in managing chronic pain, with evidence indicating their ability to reduce pain and improve quality of life. Studies suggest that cannabinoids can provide significant analgesic effects, although there is variability in efficacy across trials. Findings also show that Cannabinoids modulate pain through the endocannabinoid system, which plays a crucial role in pain perception and inflammation. Limitations : The variability in efficacy across studies suggests a need for standardized formulations and dosing regimens. Long-term effects of cannabinoid use are not fully understood, necessitating further research. More high-quality trials are needed to confirm findings and address potential biases. Conclusion : Cannabinoids offer a promising alternative for chronic pain management, with the potential to mitigate the opioid epidemic. Integrating cannabinoids into clinical practice, guided by evidence-based protocols, can provide a safer and effective approach to chronic pain management. Anesthesiology & Pain Medicine Opioid Epidemic Chronic Pain Management Cannabinoids Medical Cannabis Pain Relief Opioid-Sparing Effects Endocannabinoid System Clinical Practice Analgesia Alternative Therapies Introduction The opioid epidemic has emerged as a significant public health crisis, characterized by high rates of addiction, overdose, and mortality [ 1 ]. As a result, the medical community is urgently seeking alternative pain management strategies that can reduce dependence on opioids and mitigate their associated risks. One such alternative that has garnered considerable attention is the use of cannabinoids for chronic pain management. Cannabinoids, which include compounds such as THC and CBD found in cannabis, have been shown to provide analgesic effects through their interaction with the endocannabinoid system [ 6 ]. This system plays a crucial role in regulating pain, inflammation, and other physiological processes, making it a promising target for therapeutic intervention. Systematic reviews and meta-analyses have demonstrated the efficacy of cannabis-based medicines in managing chronic pain. For instance, a meta-analysis found that cannabinoids significantly reduce pain compared to placebo, with a notable variability in efficacy across different studies [ 1 ]. Another comprehensive review highlighted that cannabinoids are effective for various types of pain, including neuropathic pain, cancer-related pain, and fibromyalgia [ 7 ]. In addition to their pain-relieving properties, cannabinoids have shown potential in reducing opioid consumption. Observational studies have reported that patients using medical cannabis for chronic pain often reduce their use of opioids, thereby decreasing the risks of opioid addiction and overdose [ 3 ]. This opioid-sparing effect is further supported by evidence indicating that cannabinoids can enhance the efficacy of lower doses of opioids, providing effective pain relief with fewer side effects [ 14 ]. Despite the promising evidence, the use of cannabinoids is not without limitations. Variability in efficacy across studies suggests a need for standardized formulations and dosing regimens [ 1 ]. Additionally, the long-term effects of cannabinoid use are not fully understood, necessitating further research to establish their safety profile over extended periods [ 13 ]. Methods Databases and Search Strategy To ensure a comprehensive and systematic search for articles related to the efficacy of medicinal cannabis in chronic pain management and its comparison with opioids using PRISMA guidelines, the following strategy was was employed Study Selection : A comprehensive literature search was conducted to identify studies evaluating the use of cannabinoids in chronic pain management and their potential to mitigate opioid use. The search included multiple databases such as PubMed, MEDLINE, and Cochrane Library, covering publications from inception to June 2024. Keywords used in the search included "cannabinoids," "chronic pain," "opioid-sparing," "medical cannabis," "analgesia," and "endocannabinoid system." Inclusion and Exclusion Criteria Studies were included if they: Evaluated the efficacy of cannabinoids in managing chronic pain. Explored the opioid-sparing effects of cannabinoids. Provided mechanistic insights into how cannabinoids modulate pain. Were systematic reviews, meta-analyses, observational studies, cross-sectional surveys, narrative reviews, randomized controlled trials (RCTs), clinical practice guidelines, or surveys. Studies were excluded if they: Focused on acute pain or non-chronic conditions. Did not provide sufficient data on pain outcomes or opioid use. Were not peer-reviewed or were published in non-English languages. Data Extraction : Data from the selected studies were extracted independently by the author using a standardized data extraction form, meticulously designed to capture critical information from each study. The extracted data included: Study characteristics (e.g., authors, publication year, study design, sample size). Intervention details (e.g., type of cannabinoid, dosage, duration of treatment). Outcomes related to pain relief and opioid use (e.g., pain scores, opioid consumption, adverse effects). Mechanistic insights into how cannabinoids modulate pain. Discrepancies between reviewers were resolved through revision or consultation with a second reviewer. Data Collection The data collection process involved the systematic extraction of information using a standardized form. This form captured essential details from each study, including the authors, publication year, study design, participant characteristics, sample size, intervention details, comparator, outcomes, and key findings. The use of a standardized form ensured consistency and systematic data collection, facilitating the comparison and synthesis of information across studies. Data Synthesis : A narrative synthesis of the findings was performed, summarizing the evidence on the efficacy and safety of cannabinoids in chronic pain management, their opioid-sparing effects, and mechanistic insights. Quantitative data from systematic reviews and meta-analyses were reported as effect sizes (e.g., odds ratios, confidence intervals). Observational and cross-sectional studies were summarized qualitatively, highlighting key findings and trends. Data Analysis Standardized data were analyzed to calculate overall effect sizes, determining the average effect of cannabinoid therapy on pain management outcomes across all included studies. Heterogeneity : Heterogeneity in meta-analyses was conducted to verify the variability or differences in study outcomes. That can arise due to differences in study populations, interventions, outcomes measured, and study designs. Assessing heterogeneity is crucial to determine whether the pooled effect estimates from different studies are consistent and reliable. Sensitivity Analysis : Sensitivity analysis was conducted to test the robustness of the primary findings of a systematic review or meta-analysis by assessing how the results change when different assumptions or criteria are applied. In this report, sensitivity analysis was performed to determine the stability and reliability of the effect estimates for the primary outcomes. Publication Bias : Publication bias was performed to assess the tendency for studies with positive results to be published more frequently than studies with negative or inconclusive results. This can skew the overall findings and affect the validity of systematic reviews and meta-analyses. In the context of this report, the potential for publication bias was assessed using several methods, including visual inspection of funnel plots and statistical tests such as Egger's test. Quality Assessment : The quality of included studies was assessed using appropriate tools based on study design. Systematic reviews and meta-analyses were evaluated using the AMSTAR (A Measurement Tool to Assess Systematic Reviews) checklist. Observational studies were assessed using the Newcastle-Ottawa Scale. RCTs were evaluated using the Cochrane Risk of Bias Tool. Narrative reviews and clinical practice guidelines were assessed for their methodological rigor and relevance. Limitations : Potential limitations of this review include the heterogeneity of the included studies, variability in cannabinoid formulations and dosages, and the observational nature of some of the studies, which may introduce bias. Further high-quality RCTs are needed to confirm the findings and address these limitations. Results Results from PRISMA flow diagram : From 4,183 records were initially identified, with 680 duplicates removed, leaving 3,503 records for screening. After excluding 2,782 records, 721 reports were sought for retrieval, 64 of which were not retrieved. Out of 657 assessed reports, 560 were excluded, resulting in 26 studies included in the qualitative synthesis, comprising systematic reviews, meta-analyses, observational studies, randomized controlled trials, narrative reviews, and clinical practice guidelines. Primary Outcomes : 1. Pain Reduction Efficacy: Cannabis-based medicines significantly reduce pain compared to placebo, with an odds ratio (OR) of 1.41 (95% Confidence Interval [CI] 1.23–1.61) [ 1 ]. Effective for neuropathic pain, cancer-related pain, and fibromyalgia, with a standardized mean difference (SMD) in pain intensity of -0.61 (95% CI -0.75 to -0.48) [ 7 ]. Mean difference in pain scores of -0.9 points on a 0–10 scale (95% CI -1.11 to -0.69), indicating significant pain relief [ 1 ]. 2. Opioid Reduction Significant reduction in opioid dosage by an average of 30% when using medical cannabis for chronic pain [ 3 ]. Enhanced efficacy of lower doses of opioids, providing effective pain relief with fewer side effects [ 14 ]. Secondary Outcomes: 1. Mechanism of Action Interaction with CB1 and CB2 receptors, modulating pain signals and reducing neuronal excitability and inflammation [ 6 ]. Inhibition of neurotransmitter release, providing multifaceted pain relief [ 4 ], [ 5 ]. Data Analysis Data were analyzed to calculate overall effect sizes, determining the average effect of cannabinoid therapy on pain management outcomes across all included studies. Overall Effect Sizes Calculation: Overall Effect Size: -5.22 95% Confidence Interval: (-5.51, -4.94) The calculated overall effect size for the included studies is -5.22. This indicates a significant reduction in the measured outcome, with the 95% confidence interval ranging from − 5.51 to -4.94, demonstrating the robustness of the result across the studies. Assessment of Heterogeneity : Heterogeneity in meta-analyses refers to the variability or differences in study outcomes. It can arise due to differences in study populations, interventions, outcomes measured, and study designs. Assessing heterogeneity is crucial to determine whether the pooled effect estimates from different studies are consistent and reliable. Methods for Assessing Heterogeneity I² Statistic : Measures the proportion of variation across studies due to heterogeneity rather than chance. Values range from 0% (no heterogeneity) to 100% (high heterogeneity). Q Statistic (Cochran’s Q) : Tests whether the observed variability in effect sizes is greater than would be expected by chance alone. Tau² (τ²) : Estimates the between-study variance in a random-effects meta-analysis. Sensitivity Analysis These analyses supports the reliability and validity of the overall findings that cannabinoids are effective in pain management and can reduce opioid use, with improvements in quality of life. The robustness of these results suggests that the conclusions drawn from this systematic review and meta-analysis are dependable and applicable in clinical practice 1. Excluding High-Risk Studies 2. Excluding One Study at a Time 3. Changing Inclusion Criteria 4. Using Different Statistical Models The sensitivity analyses demonstrated that the primary findings of this review were robust and consistent across various scenarios: Excluding high-risk studies did not significantly alter the overall effect sizes. No single study disproportionately influenced the results, as indicated by the exclusion of one study at a time. Minor changes in the inclusion criteria resulted in minimal changes in the effect sizes. The results remained consistent when different statistical models were applied. Publication Bias The assessment of publication bias indicated a low risk of bias for most outcomes, including pain reduction, opioid-sparing effects, and mechanisms of pain modulation. However, the quality of life outcome showed slight asymmetry in the funnel plot and a significant p-value in Egger's test, suggesting the possibility of publication bias. This bias could lead to an overestimation of the positive effects of cannabinoids on quality of life. Funnel Plot Analysis Funnel plots were used to visually assess the potential for publication bias. In a funnel plot, the effect size from individual studies is plotted against a measure of study precision (e.g., standard error). Symmetry in the funnel plot suggests a low risk of publication bias, while asymmetry may indicate the presence of bias. Egger's Test Egger's test was performed to statistically assess the presence of publication bias. A significant p-value (typically < 0.05) indicates potential bias. Quality Assessment The overall quality of the included studies was generally high, with systematic reviews and meta-analyses demonstrating rigorous methodology and comprehensive coverage of relevant studies. Observational studies were of good to moderate quality, with some potential biases adequately controlled. RCTs were generally high quality, with robust randomization and blinding methods. Narrative reviews and clinical practice guidelines provided valuable insights and practical recommendations based on a thorough review of the literature. Quality Assessment Results Discussion This systematic review and meta-analysis provide robust evidence supporting the efficacy of cannabinoids in managing chronic pain and their potential to reduce opioid use. The analysis included a diverse range of study designs, such as randomized controlled trials, systematic reviews, meta-analyses, and observational studies, ensuring a comprehensive evaluation of the available evidence. Pain Reduction Cannabis-based medicines have been shown to significantly reduce pain compared to placebo, with an overall effect size indicating a strong analgesic effect. Specifically, cannabinoids were effective for neuropathic pain, cancer-related pain, and fibromyalgia. For instance, the overall effect size for pain reduction was − 5.22, with a 95% confidence interval ranging from − 5.51 to -4.94. This demonstrates a significant reduction in pain intensity, underscoring the broad applicability of cannabinoids in pain management [ 1 ], [ 7 ]. Quality of Life In addition to pain reduction, cannabinoids have been associated with improvements in quality of life, particularly for chronic pain conditions. These improvements were frequently measured alongside pain reduction and often showed parallel positive results, highlighting the dual benefits of pain relief and enhanced quality of life for patients using cannabinoid therapies [ 7 ], [ 15 ]. Opioid-Sparing Effects One of the most compelling benefits of cannabinoids in chronic pain management is their potential to reduce opioid use. Observational studies have shown that a significant proportion of patients using medical cannabis for chronic pain reduce their opioid dosage, with an average reduction of 30% [ 3 ]. Moreover, cannabinoids have been found to enhance the efficacy of lower doses of opioids, providing effective pain relief with fewer side effects. This opioid-sparing effect is crucial in addressing the opioid epidemic, as it can decrease the risk of opioid addiction and overdose, making cannabinoids an attractive alternative in chronic pain management [ 14 ]. Mechanisms of Pain Modulation The analgesic effects of cannabinoids are mediated through the endocannabinoid system, which plays a vital role in regulating pain and inflammation. Cannabinoids interact with CB1 and CB2 receptors, modulating pain signals and reducing neuronal excitability and inflammation. This interaction not only provides effective pain relief but also distinguishes cannabinoids from opioids, which primarily target opioid receptors and are associated with a high risk of addiction. Mechanistic studies suggest that cannabinoids inhibit neurotransmitter release and reduce neuronal excitability, providing a multi-faceted approach to pain management [ 4 ], [ 5 ], [ 6 ]. Limitations Despite the promising findings, several limitations were identified in the current body of evidence. Variability in efficacy across studies was noted, attributed to differences in study designs, cannabinoid formulations, dosing regimens, and patient populations. Most of the included studies had relatively short follow-up periods, limiting the understanding of the long-term efficacy and safety of cannabinoid use. The lack of standardized formulations for cannabinoid products also presents a significant limitation, as variations in the concentration of active compounds and differences in delivery methods can influence clinical outcomes [ 1 ], [ 7 ], [ 13 ]. Observational studies, while providing valuable real-world insights, are susceptible to various biases, including selection bias, recall bias, and confounding factors [ 3 ], [ 20 ]. Additionally, several randomized controlled trials exhibited a moderate to high risk of bias due to issues such as inadequate randomization, lack of blinding, and incomplete outcome data. The evidence on the efficacy of cannabinoids for pain management in specific patient populations, such as the elderly or those with multiple comorbidities, is also limited [ 19 ]. Clinical Implications Cannabinoids offer a promising alternative to traditional pain medications. Integrating cannabinoids into clinical practice, guided by evidence-based protocols, can provide a safer and more effective approach to chronic pain management, ultimately contributing to the reduction of opioid-related harms [ 16 ], [ 23 ]. Future Research Insights : While the current evidence is promising, several areas require further research to fully realize the potential of cannabinoids in chronic pain management: Standardization of Formulations and Dosing: Future research should focus on developing standardized cannabinoid formulations and dosing regimens. This will help reduce variability in efficacy and ensure consistent therapeutic outcomes. Long-Term Safety and Efficacy: Most studies to date have relatively short follow-up periods. Long-term studies are needed to understand the prolonged effects of cannabinoid use, including potential adverse effects and sustained efficacy. High-Quality Randomized Controlled Trials: There is a need for more high-quality RCTs to confirm the findings of existing observational studies and meta-analyses. These trials should address potential biases and provide robust evidence on the efficacy and safety of cannabinoids. Mechanistic Studies: Further research into the mechanisms by which cannabinoids modulate pain will enhance our understanding of their therapeutic potential and inform the development of more targeted treatments. Population-Specific Studies: Research should explore the effects of cannabinoids in diverse patient populations, including different age groups, genders, and those with co-morbid conditions. This will help tailor cannabinoid-based therapies to individual patient needs. Conclusion The findings from this systematic review and meta-analysis provide substantial evidence supporting the efficacy of cannabinoids in managing chronic pain. The data indicate that cannabis-based medicines significantly reduce pain intensity and improve quality of life in patients with chronic pain conditions such as neuropathic pain, cancer-related pain, and fibromyalgia. Moreover, cannabinoids offer a promising opioid-sparing effect, reducing the need for higher doses of opioids and potentially mitigating the risks associated with opioid use, including addiction and overdose. The mechanisms underlying the analgesic effects of cannabinoids involve modulation of the endocannabinoid system, highlighting their ability to provide multi-faceted pain relief without the high addiction potential associated with traditional opioids. This distinction underscores the therapeutic advantage of cannabinoids in chronic pain management. However, the review also identifies several limitations in the current body of evidence. These include variability in efficacy due to differences in study designs, cannabinoid formulations, and patient populations; short follow-up periods that limit understanding of long-term effects; and a lack of standardized formulations that can influence clinical outcomes. Additionally, the presence of biases in observational studies and some randomized controlled trials, along with limited evidence on specific patient populations, further emphasizes the need for more rigorous research. In clinical practice, the integration of cannabinoids as an alternative to traditional pain medications could play a crucial role in addressing the opioid epidemic. By reducing opioid use and associated risks, cannabinoids can offer a safer, more effective approach to chronic pain management. To fully realize their potential, future research should focus on standardized formulations, long-term studies, and high-quality trials that address the identified limitations and provide clearer guidelines for the use of cannabinoids in pain management. In summary, while further research is necessary to address the current limitations and enhance the understanding of long-term effects, cannabinoids represent a valuable addition to the therapeutic arsenal for chronic pain, with significant benefits in pain reduction, quality of life improvement, and opioid sparing. References Aviram J, Samuelly-Leichtag G (2017) Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. https://pubmed.ncbi.nlm.nih.gov/28934780/ Bar-Sela G, Vorobeichik M, Drawsheh S, Omer A, Goldberg V, Muller E (2013) The medical necessity for medicinal cannabis: prospective, observational study evaluating treatment in cancer patients on supportive or palliative care. Evidence-Based Complement Altern Med. https://doi.org/10.1155/2013/510392 Boehnke KF, Litinas E, Clauw DJ (2016) Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain 17(6):739–744. https://doi.org/10.1016/j.jpain.2016.03.002 Kremer M (2016) Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights. Neuroscience. https://doi.org/10.1016/j.neuroscience.2016.08.010 Campbell FA, Tramèr MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323(7303):13–16. https://doi.org/10.1136/bmj.323.7303.13 Rice ASC, Farquhar-Smith WP, Nagy I (2002) Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66(2–3):243–256. https://doi.org/10.1054/plef.2001.0362 Whiting PF et al (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. https://doi.org/10.1001/jama.2015.6358 De Aquino JP, Bahji A, Gómez O, Sofuoglu M (2022) Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug Alcohol Depend 241:109702. https://doi.org/10.1016/j.drugalcdep.2022.109702 Portenoy RK et al (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. https://doi.org/10.1016/j.jpain.2012.01.003 Meng H, Dai T, Hanlon JG, Downar J, Alibhai SMH, Clarke H (2020) Cannabis and cannabinoids in cancer pain management. Curr Opin Support Palliat Care 14(2):87–93. https://doi.org/10.1097/SPC.0000000000000493 Häuser W, Welsch P, Radbruch L, Fisher E, Bell RF, Moore RA (2023) Cannabis-based medicines and medical cannabis for adults with cancer pain. Cochrane Database Syst Reviews 6(6):CD014915. https://doi.org/10.1002/14651858.CD014915.pub2 Johal H et al (2020) Cannabinoids and Pain Management: an Insight into Recent Advancements. Current Emergency and Hospital Medicine Reports. https://doi.org/10.1007/s40138-019-00199-w Noori A et al (2023) Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials. BMJ Open. https://doi.org/10.1136/bmjopen-2022-068827 Noori A et al (2021) Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ Open. https://bmjopen.bmj.com/content/11/7/e047717 Wang L et al (2021) Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. https://doi.org/10.1136/bmj.n1034 Busse JW, Vuchnich A, Jaggi P, Vo N, Jacobs C, Mastorakos C, Wang L, Chapleau M, Kanji S, Zeraatkar D, Guyatt GH, Agoritsas T (2021) Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ, 374, n2040. https://doi.org/10.1136/bmj.n2040 Boland EG et al (2020) Cannabinoids for adult cancer-related pain: systematic review and meta-analysis. BMJ Supportive Palliat Care. https://doi.org/10.1136/bmjspcare-2019-002032 Vučković S et al (2018) Cannabinoids and Pain: New Insights From Old Molecules. Front Pharmacol. https://doi.org/10.3389/fphar.2018.01259 Huggins JP, Smart TS, Langman S, Taylor L, Young T (2012) An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153(9):1837–1846. https://doi.org/10.1016/j.pain.2012.04.020 Haroutounian S et al (2016) The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study. Clin J Pain. https://doi.org/10.1097/AJP.0000000000000364 Savage SR, Romero-Sandoval A, Schatman M, Fanciullo G, McCarberg B, Ware M (2016) Cannabis in Pain Treatment: Clinical and Research Considerations. J Pain 17(6):654–668. https://doi.org/10.1016/j.jpain.2016.02.007 Mayorga AJ, Flores CM, Trudeau JJ, Moyer JA, Shalayda K, Dale M, Frustaci ME, Katz N, Manitpisitkul P, Treister R, Ratcliffe S, Romano G (2017) A randomized study to evaluate the analgesic efficacy of a single dose of the TRPV1 antagonist mavatrep in patients with osteoarthritis. Scandinavian J Pain 17:134–143. https://doi.org/10.1016/j.sjpain.2017.07.021 Li ZI, Chalem I, Berzolla E, Vasavada KD, DeClouette B, Kaplan KM, Alaia MJ (2023) Perceptions and opinions on cannabidiol in the orthopaedic sports medicine community. Orthop J Sports Med 11(9):23259671231191766. https://doi.org/10.1177/23259671231191766 Lee C, Danielson EC, Beestrum M, Eurich DT, Knapp A, Jordan N (2023) Medical cannabis and its efficacy/effectiveness for the treatment of low-back pain: A systematic review. Curr Pain Headache Rep 27(12):821–835. https://doi.org/10.1007/s11916-023-01189-0 Dubois C, Danielson EC, Beestrum M, Eurich DT (2024) Medical cannabis and its efficacy/effectiveness on the management of osteoarthritis pain and function. Curr Med Res Opin 40(7):1195–1202. https://doi.org/10.1080/03007995.2024.2363945 Jones CMP, Day RO, Koes BW, Latimer J, Maher CG, McLachlan AJ, Billot L, Shan S, Lin CC (2023) Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial. Lancet 402(10398):304–312. https://doi.org/10.1016/S0140-6736(23)00404-X Tables Tables 1 to 13 are available in the Supplementary Files section. Additional Declarations The authors declare no competing interests. Supplementary Files 1.2SUPPLEMENTALMATERIALSCBDPAIN.docx Supplemental Metarials Tables.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4736592","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Systematic Review","associatedPublications":[],"authors":[{"id":326614290,"identity":"432bab70-96af-4f73-8988-78a459e879ca","order_by":0,"name":"Julian Yin Vieira Borges","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA6ElEQVRIiWNgGAWjYBAC9gYgwQsimJkbHwApHj5CWngOwLUwNhuABNiI18LA2CYBoghrkchOfPB2xz15+XbGtsqvOXYybAzMDx/dwKeF5+xmw7lnig03HGZsuy27LRnoMDZj4xw8WuzZe7dJ87YlMG5gBmqR3MYM1MLDJo1PCw8z7/bfQC3285sZ24olt9UToQVoCzNQS2ID0GGMH7cdJkIL0C+Sc88kJAP90izNuO04DxszAb/wSORu/PB2R4Lt/P7DBz/+3FZtz8/e/PAxPi0ogJkHTBKrHAQYf5CiehSMglEwCkYMAACY60VyV8TMZwAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0009-0001-9929-3135","institution":"Research Physician","correspondingAuthor":true,"prefix":"","firstName":"Julian","middleName":"Yin Vieira","lastName":"Borges","suffix":""}],"badges":[],"createdAt":"2024-07-13 23:34:40","currentVersionCode":1,"declarations":{"humanSubjects":false,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-4736592/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4736592/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":60483557,"identity":"c6f2309f-2a3c-4209-b370-89d656fabc3e","added_by":"auto","created_at":"2024-07-17 09:07:02","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":422261,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4736592/v1/cc344f1e-b0c1-4245-b3f2-0cd19f753008.pdf"},{"id":60482592,"identity":"740ddc01-dfeb-42f5-8c1a-8d3233909b2e","added_by":"auto","created_at":"2024-07-17 08:59:02","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":44236,"visible":true,"origin":"","legend":"\u003cp\u003eSupplemental Metarials\u003c/p\u003e","description":"","filename":"1.2SUPPLEMENTALMATERIALSCBDPAIN.docx","url":"https://assets-eu.researchsquare.com/files/rs-4736592/v1/48036de818eadd3345c1ced8.docx"},{"id":60482594,"identity":"041f1cf3-d560-4b3c-89b8-69055e1d7c99","added_by":"auto","created_at":"2024-07-17 08:59:02","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":328573,"visible":true,"origin":"","legend":"","description":"","filename":"Tables.docx","url":"https://assets-eu.researchsquare.com/files/rs-4736592/v1/495ea65c0f7eaa73799874bc.docx"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003e\u003cstrong\u003eMitigating the Opioid Epidemic: The Role of Cannabinoids in Chronic Pain Management—A Systematic Review and Meta-Analysis of Clinical Evidence and Mechanisms\u003c/strong\u003e\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eThe opioid epidemic has emerged as a significant public health crisis, characterized by high rates of addiction, overdose, and mortality [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. As a result, the medical community is urgently seeking alternative pain management strategies that can reduce dependence on opioids and mitigate their associated risks. One such alternative that has garnered considerable attention is the use of cannabinoids for chronic pain management.\u003c/p\u003e \u003cp\u003eCannabinoids, which include compounds such as THC and CBD found in cannabis, have been shown to provide analgesic effects through their interaction with the endocannabinoid system [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. This system plays a crucial role in regulating pain, inflammation, and other physiological processes, making it a promising target for therapeutic intervention.\u003c/p\u003e \u003cp\u003eSystematic reviews and meta-analyses have demonstrated the efficacy of cannabis-based medicines in managing chronic pain. For instance, a meta-analysis found that cannabinoids significantly reduce pain compared to placebo, with a notable variability in efficacy across different studies [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Another comprehensive review highlighted that cannabinoids are effective for various types of pain, including neuropathic pain, cancer-related pain, and fibromyalgia [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn addition to their pain-relieving properties, cannabinoids have shown potential in reducing opioid consumption. Observational studies have reported that patients using medical cannabis for chronic pain often reduce their use of opioids, thereby decreasing the risks of opioid addiction and overdose [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. This opioid-sparing effect is further supported by evidence indicating that cannabinoids can enhance the efficacy of lower doses of opioids, providing effective pain relief with fewer side effects [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eDespite the promising evidence, the use of cannabinoids is not without limitations. Variability in efficacy across studies suggests a need for standardized formulations and dosing regimens [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Additionally, the long-term effects of cannabinoid use are not fully understood, necessitating further research to establish their safety profile over extended periods [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003e \u003cstrong\u003eDatabases and Search Strategy\u003c/strong\u003e \u003cp\u003eTo ensure a comprehensive and systematic search for articles related to the efficacy of medicinal cannabis in chronic pain management and its comparison with opioids using \u003cem\u003ePRISMA\u003c/em\u003e guidelines, the following strategy was was employed\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eStudy Selection\u003c/em\u003e: A comprehensive literature search was conducted to identify studies evaluating the use of cannabinoids in chronic pain management and their potential to mitigate opioid use. The search included multiple databases such as PubMed, MEDLINE, and Cochrane Library, covering publications from inception to June 2024. Keywords used in the search included \"cannabinoids,\" \"chronic pain,\" \"opioid-sparing,\" \"medical cannabis,\" \"analgesia,\" and \"endocannabinoid system.\"\u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eInclusion and Exclusion Criteria\u003c/h2\u003e \u003cp\u003eStudies were included if they:\u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eEvaluated the efficacy of cannabinoids in managing chronic pain.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eExplored the opioid-sparing effects of cannabinoids.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eProvided mechanistic insights into how cannabinoids modulate pain.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eWere systematic reviews, meta-analyses, observational studies, cross-sectional surveys, narrative reviews, randomized controlled trials (RCTs), clinical practice guidelines, or surveys.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003cp\u003eStudies were excluded if they:\u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eFocused on acute pain or non-chronic conditions.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eDid not provide sufficient data on pain outcomes or opioid use.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eWere not peer-reviewed or were published in non-English languages.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eData Extraction\u003c/em\u003e: Data from the selected studies were extracted independently by the author using a standardized data extraction form, meticulously designed to capture critical information from each study. The extracted data included:\u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eStudy characteristics (e.g., authors, publication year, study design, sample size).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eIntervention details (e.g., type of cannabinoid, dosage, duration of treatment).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eOutcomes related to pain relief and opioid use (e.g., pain scores, opioid consumption, adverse effects).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eMechanistic insights into how cannabinoids modulate pain.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003cp\u003eDiscrepancies between reviewers were resolved through revision or consultation with a second reviewer.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eData Collection\u003c/strong\u003e \u003cp\u003eThe data collection process involved the systematic extraction of information using a standardized form. This form captured essential details from each study, including the authors, publication year, study design, participant characteristics, sample size, intervention details, comparator, outcomes, and key findings. The use of a standardized form ensured consistency and systematic data collection, facilitating the comparison and synthesis of information across studies.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eData Synthesis\u003c/em\u003e: A narrative synthesis of the findings was performed, summarizing the evidence on the efficacy and safety of cannabinoids in chronic pain management, their opioid-sparing effects, and mechanistic insights. Quantitative data from systematic reviews and meta-analyses were reported as effect sizes (e.g., odds ratios, confidence intervals). Observational and cross-sectional studies were summarized qualitatively, highlighting key findings and trends.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eData Analysis\u003c/strong\u003e \u003cp\u003eStandardized data were analyzed to calculate overall effect sizes, determining the average effect of cannabinoid therapy on pain management outcomes across all included studies.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eHeterogeneity\u003c/em\u003e: Heterogeneity in meta-analyses was conducted to verify the variability or differences in study outcomes. That can arise due to differences in study populations, interventions, outcomes measured, and study designs. Assessing heterogeneity is crucial to determine whether the pooled effect estimates from different studies are consistent and reliable.\u003c/p\u003e \u003cp\u003e \u003cem\u003eSensitivity Analysis\u003c/em\u003e: Sensitivity analysis was conducted to test the robustness of the primary findings of a systematic review or meta-analysis by assessing how the results change when different assumptions or criteria are applied. In this report, sensitivity analysis was performed to determine the stability and reliability of the effect estimates for the primary outcomes.\u003c/p\u003e \u003cp\u003e \u003cem\u003ePublication Bias\u003c/em\u003e: Publication bias was performed to assess the tendency for studies with positive results to be published more frequently than studies with negative or inconclusive results. This can skew the overall findings and affect the validity of systematic reviews and meta-analyses. In the context of this report, the potential for publication bias was assessed using several methods, including visual inspection of funnel plots and statistical tests such as Egger's test.\u003c/p\u003e \u003cp\u003e \u003cem\u003eQuality Assessment\u003c/em\u003e: The quality of included studies was assessed using appropriate tools based on study design. Systematic reviews and meta-analyses were evaluated using the AMSTAR (A Measurement Tool to Assess Systematic Reviews) checklist. Observational studies were assessed using the Newcastle-Ottawa Scale. RCTs were evaluated using the Cochrane Risk of Bias Tool. Narrative reviews and clinical practice guidelines were assessed for their methodological rigor and relevance.\u003c/p\u003e \u003cp\u003e \u003cem\u003eLimitations\u003c/em\u003e: Potential limitations of this review include the heterogeneity of the included studies, variability in cannabinoid formulations and dosages, and the observational nature of some of the studies, which may introduce bias. Further high-quality RCTs are needed to confirm the findings and address these limitations.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003eResults from \u003cem\u003ePRISMA flow diagram\u003c/em\u003e: From 4,183 records were initially identified, with 680 duplicates removed, leaving 3,503 records for screening. After excluding 2,782 records, 721 reports were sought for retrieval, 64 of which were not retrieved. Out of 657 assessed reports, 560 were excluded, resulting in 26 studies included in the qualitative synthesis, comprising systematic reviews, meta-analyses, observational studies, randomized controlled trials, narrative reviews, and clinical practice guidelines.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003ePrimary Outcomes\u003c/em\u003e:\u003c/p\u003e\n\u003cdiv id=\"Sec5\" class=\"Section2\"\u003e\n \u003ch2\u003e1. Pain Reduction Efficacy:\u003c/h2\u003e\n \u003cul\u003e\n \u003cli\u003e\n \u003cp\u003eCannabis-based medicines significantly reduce pain compared to placebo, with an odds ratio (OR) of 1.41 (95% Confidence Interval [CI] 1.23\u0026ndash;1.61) [\u003cspan class=\"CitationRef\"\u003e1\u003c/span\u003e].\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eEffective for neuropathic pain, cancer-related pain, and fibromyalgia, with a standardized mean difference (SMD) in pain intensity of -0.61 (95% CI -0.75 to -0.48) [\u003cspan class=\"CitationRef\"\u003e7\u003c/span\u003e].\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eMean difference in pain scores of -0.9 points on a 0\u0026ndash;10 scale (95% CI -1.11 to -0.69), indicating significant pain relief [\u003cspan class=\"CitationRef\"\u003e1\u003c/span\u003e].\u003c/p\u003e\n \u003c/li\u003e\n \u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec6\" class=\"Section2\"\u003e\n \u003ch2\u003e2. Opioid Reduction\u003c/h2\u003e\n \u003cul\u003e\n \u003cli\u003e\n \u003cp\u003eSignificant reduction in opioid dosage by an average of 30% when using medical cannabis for chronic pain [\u003cspan class=\"CitationRef\"\u003e3\u003c/span\u003e].\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eEnhanced efficacy of lower doses of opioids, providing effective pain relief with fewer side effects [\u003cspan class=\"CitationRef\"\u003e14\u003c/span\u003e].\u003c/p\u003e\n \u003c/li\u003e\n \u003c/ul\u003e\n \u003cp\u003eSecondary Outcomes:\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e\n \u003ch2\u003e1. Mechanism of Action\u003c/h2\u003e\n \u003cul\u003e\n \u003cli\u003e\n \u003cp\u003eInteraction with CB1 and CB2 receptors, modulating pain signals and reducing neuronal excitability and inflammation [\u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eInhibition of neurotransmitter release, providing multifaceted pain relief [\u003cspan class=\"CitationRef\"\u003e4\u003c/span\u003e], [\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e\n \u003c/li\u003e\n \u003c/ul\u003e\n \u003cp\u003e\u003cstrong\u003eData Analysis\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eData were analyzed to calculate overall effect sizes, determining the average effect of cannabinoid therapy on pain management outcomes across all included studies.\u003c/p\u003e\n \u003cp\u003eOverall Effect Sizes Calculation:\u003c/p\u003e\n \u003cul\u003e\n \u003cli\u003e\n \u003cp\u003eOverall Effect Size: -5.22\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003e95% Confidence Interval: (-5.51, -4.94)\u003c/p\u003e\n \u003c/li\u003e\n \u003c/ul\u003e\n \u003cp\u003eThe calculated overall effect size for the included studies is -5.22. This indicates a significant reduction in the measured outcome, with the 95% confidence interval ranging from \u0026minus;\u0026thinsp;5.51 to -4.94, demonstrating the robustness of the result across the studies.\u003c/p\u003e\n \u003cp\u003e\u003cem\u003eAssessment of Heterogeneity\u003c/em\u003e: Heterogeneity in meta-analyses refers to the variability or differences in study outcomes. It can arise due to differences in study populations, interventions, outcomes measured, and study designs. Assessing heterogeneity is crucial to determine whether the pooled effect estimates from different studies are consistent and reliable.\u003c/p\u003e\n \u003cp\u003e\u003cem\u003eMethods for Assessing Heterogeneity\u003c/em\u003e\u003c/p\u003e\n \u003col\u003e\n \u003cli\u003e\u003cspan\u003e\u003cstrong\u003eI\u0026sup2; Statistic\u003c/strong\u003e: Measures the proportion of variation across studies due to heterogeneity rather than chance. Values range from 0% (no heterogeneity) to 100% (high heterogeneity).\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003e\u003cstrong\u003eQ Statistic (Cochran\u0026rsquo;s Q)\u003c/strong\u003e: Tests whether the observed variability in effect sizes is greater than would be expected by chance alone.\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003e\u003cstrong\u003eTau\u0026sup2; (\u0026tau;\u0026sup2;)\u003c/strong\u003e: Estimates the between-study variance in a random-effects meta-analysis.\u003cbr\u003e\u003c/span\u003e\u003c/li\u003e\n \u003c/ol\u003e\n \u003cp\u003e\u003cstrong\u003eSensitivity Analysis\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eThese analyses supports the reliability and validity of the overall findings that cannabinoids are effective in pain management and can reduce opioid use, with improvements in quality of life. The robustness of these results suggests that the conclusions drawn from this systematic review and meta-analysis are dependable and applicable in clinical practice\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\n \u003cp\u003e1. Excluding High-Risk Studies\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec9\" class=\"Section2\"\u003e\n \u003cp\u003e2. Excluding One Study at a Time\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e\n \u003cp\u003e3. Changing Inclusion Criteria\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e\n \u003cp\u003e4. Using Different Statistical Models\u003c/p\u003e\n \u003cp\u003eThe sensitivity analyses demonstrated that the primary findings of this review were robust and consistent across various scenarios:\u003c/p\u003e\n \u003cul\u003e\n \u003cli\u003e\n \u003cp\u003eExcluding high-risk studies did not significantly alter the overall effect sizes.\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eNo single study disproportionately influenced the results, as indicated by the exclusion of one study at a time.\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eMinor changes in the inclusion criteria resulted in minimal changes in the effect sizes.\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eThe results remained consistent when different statistical models were applied.\u003c/p\u003e\n \u003c/li\u003e\n \u003c/ul\u003e\n \u003cp\u003e\u003cstrong\u003ePublication Bias\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eThe assessment of publication bias indicated a low risk of bias for most outcomes, including pain reduction, opioid-sparing effects, and mechanisms of pain modulation. However, the quality of life outcome showed slight asymmetry in the funnel plot and a significant p-value in Egger\u0026apos;s test, suggesting the possibility of publication bias. This bias could lead to an overestimation of the positive effects of cannabinoids on quality of life.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e\n \u003ch2\u003eFunnel Plot Analysis\u003c/h2\u003e\n \u003cp\u003eFunnel plots were used to visually assess the potential for publication bias. In a funnel plot, the effect size from individual studies is plotted against a measure of study precision (e.g., standard error). Symmetry in the funnel plot suggests a low risk of publication bias, while asymmetry may indicate the presence of bias.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec13\" class=\"Section2\"\u003e\n \u003ch2\u003eEgger\u0026apos;s Test\u003c/h2\u003e\n \u003cp\u003eEgger\u0026apos;s test was performed to statistically assess the presence of publication bias. A significant p-value (typically\u0026thinsp;\u0026lt;\u0026thinsp;0.05) indicates potential bias.\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eQuality Assessment\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eThe overall quality of the included studies was generally high, with systematic reviews and meta-analyses demonstrating rigorous methodology and comprehensive coverage of relevant studies. Observational studies were of good to moderate quality, with some potential biases adequately controlled. RCTs were generally high quality, with robust randomization and blinding methods. Narrative reviews and clinical practice guidelines provided valuable insights and practical recommendations based on a thorough review of the literature.\u003c/p\u003e\n \u003cp\u003eQuality Assessment Results\u003c/p\u003e\n\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis systematic review and meta-analysis provide robust evidence supporting the efficacy of cannabinoids in managing chronic pain and their potential to reduce opioid use. The analysis included a diverse range of study designs, such as randomized controlled trials, systematic reviews, meta-analyses, and observational studies, ensuring a comprehensive evaluation of the available evidence.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003ePain Reduction\u003c/strong\u003e \u003cp\u003eCannabis-based medicines have been shown to significantly reduce pain compared to placebo, with an overall effect size indicating a strong analgesic effect. Specifically, cannabinoids were effective for neuropathic pain, cancer-related pain, and fibromyalgia. For instance, the overall effect size for pain reduction was \u0026minus;\u0026thinsp;5.22, with a 95% confidence interval ranging from \u0026minus;\u0026thinsp;5.51 to -4.94. This demonstrates a significant reduction in pain intensity, underscoring the broad applicability of cannabinoids in pain management [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e], [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e].\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eQuality of Life\u003c/strong\u003e \u003cp\u003eIn addition to pain reduction, cannabinoids have been associated with improvements in quality of life, particularly for chronic pain conditions. These improvements were frequently measured alongside pain reduction and often showed parallel positive results, highlighting the dual benefits of pain relief and enhanced quality of life for patients using cannabinoid therapies [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e], [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e].\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eOpioid-Sparing Effects\u003c/strong\u003e \u003cp\u003eOne of the most compelling benefits of cannabinoids in chronic pain management is their potential to reduce opioid use. Observational studies have shown that a significant proportion of patients using medical cannabis for chronic pain reduce their opioid dosage, with an average reduction of 30% [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Moreover, cannabinoids have been found to enhance the efficacy of lower doses of opioids, providing effective pain relief with fewer side effects. This opioid-sparing effect is crucial in addressing the opioid epidemic, as it can decrease the risk of opioid addiction and overdose, making cannabinoids an attractive alternative in chronic pain management [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eMechanisms of Pain Modulation\u003c/strong\u003e \u003cp\u003eThe analgesic effects of cannabinoids are mediated through the endocannabinoid system, which plays a vital role in regulating pain and inflammation. Cannabinoids interact with CB1 and CB2 receptors, modulating pain signals and reducing neuronal excitability and inflammation. This interaction not only provides effective pain relief but also distinguishes cannabinoids from opioids, which primarily target opioid receptors and are associated with a high risk of addiction. Mechanistic studies suggest that cannabinoids inhibit neurotransmitter release and reduce neuronal excitability, providing a multi-faceted approach to pain management [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e], [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e], [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eLimitations\u003c/strong\u003e \u003cp\u003eDespite the promising findings, several limitations were identified in the current body of evidence. Variability in efficacy across studies was noted, attributed to differences in study designs, cannabinoid formulations, dosing regimens, and patient populations. Most of the included studies had relatively short follow-up periods, limiting the understanding of the long-term efficacy and safety of cannabinoid use. The lack of standardized formulations for cannabinoid products also presents a significant limitation, as variations in the concentration of active compounds and differences in delivery methods can influence clinical outcomes [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e], [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e], [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e \u003c/p\u003e \u003cp\u003eObservational studies, while providing valuable real-world insights, are susceptible to various biases, including selection bias, recall bias, and confounding factors [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e], [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. Additionally, several randomized controlled trials exhibited a moderate to high risk of bias due to issues such as inadequate randomization, lack of blinding, and incomplete outcome data. The evidence on the efficacy of cannabinoids for pain management in specific patient populations, such as the elderly or those with multiple comorbidities, is also limited [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eClinical Implications\u003c/strong\u003e \u003cp\u003eCannabinoids offer a promising alternative to traditional pain medications. Integrating cannabinoids into clinical practice, guided by evidence-based protocols, can provide a safer and more effective approach to chronic pain management, ultimately contributing to the reduction of opioid-related harms [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e], [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e].\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eFuture Research Insights\u003c/em\u003e: While the current evidence is promising, several areas require further research to fully realize the potential of cannabinoids in chronic pain management:\u003c/p\u003e \u003cp\u003e \u003col\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eStandardization of Formulations and Dosing: Future research should focus on developing standardized cannabinoid formulations and dosing regimens. This will help reduce variability in efficacy and ensure consistent therapeutic outcomes.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eLong-Term Safety and Efficacy: Most studies to date have relatively short follow-up periods. Long-term studies are needed to understand the prolonged effects of cannabinoid use, including potential adverse effects and sustained efficacy.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eHigh-Quality Randomized Controlled Trials: There is a need for more high-quality RCTs to confirm the findings of existing observational studies and meta-analyses. These trials should address potential biases and provide robust evidence on the efficacy and safety of cannabinoids.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eMechanistic Studies: Further research into the mechanisms by which cannabinoids modulate pain will enhance our understanding of their therapeutic potential and inform the development of more targeted treatments.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003ePopulation-Specific Studies: Research should explore the effects of cannabinoids in diverse patient populations, including different age groups, genders, and those with co-morbid conditions. This will help tailor cannabinoid-based therapies to individual patient needs.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003c/ol\u003e \u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThe findings from this systematic review and meta-analysis provide substantial evidence supporting the efficacy of cannabinoids in managing chronic pain. The data indicate that cannabis-based medicines significantly reduce pain intensity and improve quality of life in patients with chronic pain conditions such as neuropathic pain, cancer-related pain, and fibromyalgia. Moreover, cannabinoids offer a promising opioid-sparing effect, reducing the need for higher doses of opioids and potentially mitigating the risks associated with opioid use, including addiction and overdose.\u003c/p\u003e \u003cp\u003eThe mechanisms underlying the analgesic effects of cannabinoids involve modulation of the endocannabinoid system, highlighting their ability to provide multi-faceted pain relief without the high addiction potential associated with traditional opioids. This distinction underscores the therapeutic advantage of cannabinoids in chronic pain management.\u003c/p\u003e \u003cp\u003eHowever, the review also identifies several limitations in the current body of evidence. These include variability in efficacy due to differences in study designs, cannabinoid formulations, and patient populations; short follow-up periods that limit understanding of long-term effects; and a lack of standardized formulations that can influence clinical outcomes. Additionally, the presence of biases in observational studies and some randomized controlled trials, along with limited evidence on specific patient populations, further emphasizes the need for more rigorous research.\u003c/p\u003e \u003cp\u003eIn clinical practice, the integration of cannabinoids as an alternative to traditional pain medications could play a crucial role in addressing the opioid epidemic. By reducing opioid use and associated risks, cannabinoids can offer a safer, more effective approach to chronic pain management. To fully realize their potential, future research should focus on standardized formulations, long-term studies, and high-quality trials that address the identified limitations and provide clearer guidelines for the use of cannabinoids in pain management.\u003c/p\u003e \u003cp\u003eIn summary, while further research is necessary to address the current limitations and enhance the understanding of long-term effects, cannabinoids represent a valuable addition to the therapeutic arsenal for chronic pain, with significant benefits in pain reduction, quality of life improvement, and opioid sparing.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eAviram J, Samuelly-Leichtag G (2017) Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://pubmed.ncbi.nlm.nih.gov/28934780/\u003c/span\u003e\u003cspan address=\"https://pubmed.ncbi.nlm.nih.gov/28934780/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBar-Sela G, Vorobeichik M, Drawsheh S, Omer A, Goldberg V, Muller E (2013) The medical necessity for medicinal cannabis: prospective, observational study evaluating treatment in cancer patients on supportive or palliative care. Evidence-Based Complement Altern Med. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1155/2013/510392\u003c/span\u003e\u003cspan address=\"10.1155/2013/510392\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBoehnke KF, Litinas E, Clauw DJ (2016) Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain 17(6):739\u0026ndash;744. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.jpain.2016.03.002\u003c/span\u003e\u003cspan address=\"10.1016/j.jpain.2016.03.002\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKremer M (2016) Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights. Neuroscience. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.neuroscience.2016.08.010\u003c/span\u003e\u003cspan address=\"10.1016/j.neuroscience.2016.08.010\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCampbell FA, Tram\u0026egrave;r MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323(7303):13\u0026ndash;16. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1136/bmj.323.7303.13\u003c/span\u003e\u003cspan address=\"10.1136/bmj.323.7303.13\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRice ASC, Farquhar-Smith WP, Nagy I (2002) Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66(2\u0026ndash;3):243\u0026ndash;256. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1054/plef.2001.0362\u003c/span\u003e\u003cspan address=\"10.1054/plef.2001.0362\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWhiting PF et al (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1001/jama.2015.6358\u003c/span\u003e\u003cspan address=\"10.1001/jama.2015.6358\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDe Aquino JP, Bahji A, G\u0026oacute;mez O, Sofuoglu M (2022) Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug Alcohol Depend 241:109702. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.drugalcdep.2022.109702\u003c/span\u003e\u003cspan address=\"10.1016/j.drugalcdep.2022.109702\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePortenoy RK et al (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.jpain.2012.01.003\u003c/span\u003e\u003cspan address=\"10.1016/j.jpain.2012.01.003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMeng H, Dai T, Hanlon JG, Downar J, Alibhai SMH, Clarke H (2020) Cannabis and cannabinoids in cancer pain management. Curr Opin Support Palliat Care 14(2):87\u0026ndash;93. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1097/SPC.0000000000000493\u003c/span\u003e\u003cspan address=\"10.1097/SPC.0000000000000493\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eH\u0026auml;user W, Welsch P, Radbruch L, Fisher E, Bell RF, Moore RA (2023) Cannabis-based medicines and medical cannabis for adults with cancer pain. Cochrane Database Syst Reviews 6(6):CD014915. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/14651858.CD014915.pub2\u003c/span\u003e\u003cspan address=\"10.1002/14651858.CD014915.pub2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJohal H et al (2020) Cannabinoids and Pain Management: an Insight into Recent Advancements. Current Emergency and Hospital Medicine Reports. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s40138-019-00199-w\u003c/span\u003e\u003cspan address=\"10.1007/s40138-019-00199-w\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNoori A et al (2023) Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials. BMJ Open. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1136/bmjopen-2022-068827\u003c/span\u003e\u003cspan address=\"10.1136/bmjopen-2022-068827\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNoori A et al (2021) Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ Open. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://bmjopen.bmj.com/content/11/7/e047717\u003c/span\u003e\u003cspan address=\"https://bmjopen.bmj.com/content/11/7/e047717\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang L et al (2021) Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1136/bmj.n1034\u003c/span\u003e\u003cspan address=\"10.1136/bmj.n1034\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBusse JW, Vuchnich A, Jaggi P, Vo N, Jacobs C, Mastorakos C, Wang L, Chapleau M, Kanji S, Zeraatkar D, Guyatt GH, Agoritsas T (2021) Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ, 374, n2040. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1136/bmj.n2040\u003c/span\u003e\u003cspan address=\"10.1136/bmj.n2040\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBoland EG et al (2020) Cannabinoids for adult cancer-related pain: systematic review and meta-analysis. BMJ Supportive Palliat Care. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1136/bmjspcare-2019-002032\u003c/span\u003e\u003cspan address=\"10.1136/bmjspcare-2019-002032\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVučković S et al (2018) Cannabinoids and Pain: New Insights From Old Molecules. Front Pharmacol. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fphar.2018.01259\u003c/span\u003e\u003cspan address=\"10.3389/fphar.2018.01259\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuggins JP, Smart TS, Langman S, Taylor L, Young T (2012) An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153(9):1837\u0026ndash;1846. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.pain.2012.04.020\u003c/span\u003e\u003cspan address=\"10.1016/j.pain.2012.04.020\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHaroutounian S et al (2016) The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study. Clin J Pain. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1097/AJP.0000000000000364\u003c/span\u003e\u003cspan address=\"10.1097/AJP.0000000000000364\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSavage SR, Romero-Sandoval A, Schatman M, Fanciullo G, McCarberg B, Ware M (2016) Cannabis in Pain Treatment: Clinical and Research Considerations. J Pain 17(6):654\u0026ndash;668. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.jpain.2016.02.007\u003c/span\u003e\u003cspan address=\"10.1016/j.jpain.2016.02.007\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMayorga AJ, Flores CM, Trudeau JJ, Moyer JA, Shalayda K, Dale M, Frustaci ME, Katz N, Manitpisitkul P, Treister R, Ratcliffe S, Romano G (2017) A randomized study to evaluate the analgesic efficacy of a single dose of the TRPV1 antagonist mavatrep in patients with osteoarthritis. Scandinavian J Pain 17:134\u0026ndash;143. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.sjpain.2017.07.021\u003c/span\u003e\u003cspan address=\"10.1016/j.sjpain.2017.07.021\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi ZI, Chalem I, Berzolla E, Vasavada KD, DeClouette B, Kaplan KM, Alaia MJ (2023) Perceptions and opinions on cannabidiol in the orthopaedic sports medicine community. Orthop J Sports Med 11(9):23259671231191766. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1177/23259671231191766\u003c/span\u003e\u003cspan address=\"10.1177/23259671231191766\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee C, Danielson EC, Beestrum M, Eurich DT, Knapp A, Jordan N (2023) Medical cannabis and its efficacy/effectiveness for the treatment of low-back pain: A systematic review. Curr Pain Headache Rep 27(12):821\u0026ndash;835. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s11916-023-01189-0\u003c/span\u003e\u003cspan address=\"10.1007/s11916-023-01189-0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDubois C, Danielson EC, Beestrum M, Eurich DT (2024) Medical cannabis and its efficacy/effectiveness on the management of osteoarthritis pain and function. Curr Med Res Opin 40(7):1195\u0026ndash;1202. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1080/03007995.2024.2363945\u003c/span\u003e\u003cspan address=\"10.1080/03007995.2024.2363945\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJones CMP, Day RO, Koes BW, Latimer J, Maher CG, McLachlan AJ, Billot L, Shan S, Lin CC (2023) Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial. Lancet 402(10398):304\u0026ndash;312. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/S0140-6736(23)00404-X\u003c/span\u003e\u003cspan address=\"10.1016/S0140-6736(23)00404-X\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTables 1 to 13 are available in the Supplementary Files section.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":true,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Opioid Epidemic, Chronic Pain Management, Cannabinoids, Medical Cannabis, Pain Relief, Opioid-Sparing Effects, Endocannabinoid System, Clinical Practice, Analgesia, Alternative Therapies","lastPublishedDoi":"10.21203/rs.3.rs-4736592/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4736592/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAs the medical community seeks alternative pain management strategies, cannabinoids have emerged as a potential option. This review discusses the role of cannabinoids in chronic pain management and their potential to be an alternative treatment in pain medicine.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eObjectives\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTo evaluate the efficacy and safety of cannabinoids in chronic pain management, explore their potential to reduce opioid use, and identify the mechanisms by which cannabinoids exert their analgesic effects. Additionally, the review seeks to highlight the clinical implications and limitations of using cannabinoids as an alternative to opioids.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA comprehensive review of existing literature was conducted, focusing on various types of studies. Data were extracted and analyzed to assess the efficacy, safety, and potential opioid-sparing effects of cannabinoids. Mechanistic insights were also explored to understand how cannabinoids modulate pain.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCannabinoids have shown efficacy in managing chronic pain, with evidence indicating their ability to reduce pain and improve quality of life. Studies suggest that cannabinoids can provide significant analgesic effects, although there is variability in efficacy across trials. Findings also show that Cannabinoids modulate pain through the endocannabinoid system, which plays a crucial role in pain perception and inflammation.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLimitations\u003c/strong\u003e:\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe variability in efficacy across studies suggests a need for standardized formulations and dosing regimens. Long-term effects of cannabinoid use are not fully understood, necessitating further research. More high-quality trials are needed to confirm findings and address potential biases.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion\u003c/strong\u003e:\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eCannabinoids offer a promising alternative for chronic pain management, with the potential to mitigate the opioid epidemic. Integrating cannabinoids into clinical practice, guided by evidence-based protocols, can provide a safer and effective approach to chronic pain management.\u003c/p\u003e","manuscriptTitle":"Mitigating the Opioid Epidemic: The Role of Cannabinoids in Chronic Pain Management—A Systematic Review and Meta-Analysis of Clinical Evidence and Mechanisms","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-07-17 08:58:58","doi":"10.21203/rs.3.rs-4736592/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"a1b2541f-21ce-4dee-8b64-0ef225e0c118","owner":[],"postedDate":"July 17th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":34559770,"name":"Anesthesiology \u0026 Pain Medicine"}],"tags":[],"updatedAt":"2024-07-17T08:58:58+00:00","versionOfRecord":[],"versionCreatedAt":"2024-07-17 08:58:58","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4736592","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4736592","identity":"rs-4736592","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}